Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
It is marketed as an alternative to cannabis by drug dealers but, chemically, the two drugs are very different. Cannabis ...
Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year ...
A multidisciplinary approach, including ketamine withdrawal and symptom management, is essential to mitigate long-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback